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Mitochondrial Permeability transition poreTreatment with the ω-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) exerts cardioprotective effects, and suppresses Ca2+-induced opening of the
mitochondrial permeability transition pore (MPTP). These effects are associated with increased DHA and
EPA, and lower arachidonic acid (ARA) in cardiac phospholipids. While clinical studies suggest the
triglyceride lowering effects of DHA and EPA are equivalent, little is known about the independent effects of
DHA and EPA on mitochondria function. We compared the effects of dietary supplementation with the ω-3
PUFAs DHA and EPA on cardiac mitochondrial phospholipid fatty acid composition and Ca2+-induced MPTP
opening. Rats were fed a standard lab diet with either normal low levels of ω-3 PUFA, or DHA or EPA at 2.5%
of energy intake for 8 weeks, and cardiac mitochondria were isolated and analyzed for Ca2+-induced MPTP
opening and phospholipid fatty acyl composition. DHA supplementation increased both DHA and EPA and
decreased ARA in mitochondrial phospholipid, and signiﬁcantly delayed MPTP opening as assessed by
increased Ca2+ retention capacity and decreased Ca2+-induced mitochondria swelling. EPA supplementation
increased EPA in mitochondrial phospholipids, but did not affect DHA, only modestly lowered ARA, and did
not affect MPTP opening. In summary, dietary supplementation with DHA but not EPA, profoundly altered
mitochondrial phospholipid fatty acid composition and delayed Ca2+-induced MPTP opening.orin A; DHA, docosahexaenoic
permeability transition pore;
dant anion channel
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Cardiac mitochondria are important not only for maintaining
sufﬁcient ATP generation, but also for prevention of cell death and loss
of cardiomyocytes. Opening of the mitochondrial permeability
transition pore (MPTP) leads to cell death, and has been implicated
in ischemic injury and the development and progression of heart
failure [1,23], thus pharmacological prevention of MPTP is a target for
cardioprotective therapy [5,13,17,34]. The MPTP is a large diameter,
high conductance, voltage-dependent channel that allows passage of
water, ions, and molecules up to ∼1.5 kDa [13,34]. Mitochondrialaccumulation of high levels of Ca2+ triggers MPTP opening, while
Ca2+ chelation causes it to rapidly close. The molecular components
and structure of the pore are not precisely known [13], however
recent data suggest MPTP opening is affected by the composition of
mitochondrial membrane phospholipids [24].
Pharmacological doses of the ω-3 polyunsaturated fatty acids
(PUFAs) docosahexaenoic acid (DHA (22:6n3)) and eicosapentaenoic
acid (EPA (20:5n3)) from ﬁsh oils are used clinically to lower plasma
triglycerides, however they may also decreased ischemic injury, and
prevent the development and progression of heart failure [8,9,11,27].
The mechanisms for these effects are not clear, but may be dependent
upon changes in cardiac phospholipid composition and improved
mitochondrial tolerance to stress. We recently found that dietary
supplementation with a mixture of EPA and DHA increased the
mitochondrial phospholipid content of DHA and EPA, and decreased
arachidonic acid (ARA; 20:4n6) [24]. ARA is the precursor to pro-
inﬂammatory prostaglandins, thromboxanes and leukotrienes. Re-
lease of ARA from cell membranes can trigger MPTP opening and is
implicated in cell death by either necrosis or apoptosis [18,26,29,35].
Table 1
Fatty acid compositions of the rodent diets expressed as the molar percent of total fatty
acids in the diet. In Series 1 all diets had 12% of total energy from fat, 20% from protein
and 68% from carbohydrate, and in Series 2 all diets had 14% of total energy from fat,
20% from protein and 66% from carbohydrate.
Fatty
acid
Series 1 Series 2
CTRL DHA EPA CRTL DHA
C12:0 3.9 2.2 3.9 3.4 1.5
C14:0 1.7 4.9 1.3 1.1 3.6
C16:0 21.6 14.7 13.1 21.7 14.6
C16:1 1.7 1.8 – 0.2 1.4
C18:0 18.9 13.8 14.0 25.8 14.2
C18:1n-9 34.9 29.7 31.6 30.3 28.8
C18:2n-6 13.9 11.1 13.0 13.9 14.7
C18:3n-3 1.8 1.3 1.3 2.2 2.2
C20:5n-3 – – 19.1 – –
C22:6n-3 – 19.1 – – 17.8
Table 2
Body mass, organ mass, and mitochondrial yield.
Control DHA EPA
Terminal body mass (g) 503±15 501±19 486±29
LV mass (g) 0.92±0.04 0.94±0.05 0.89±0.07
RV mass (g) 0.32±0.01 0.30±0.02 0.29±0.03
Biatrial mass (g) 0.09±0.01 0.08±0.01 0.09±0.02
Liver mass (g) 16.0±1.1 14.8±0.5 15.5±1.5
Mitochondrial yield (mg mito
protein/g wet wt)
18.1±3.0 18.1±2.2 19.0±1.5
1556 R.J. Khairallah et al. / Biochimica et Biophysica Acta 1797 (2010) 1555–1562Both DHA and EPA can decrease ARA through inhibition of the
elongation of linoleic acid [8]. We showed that dietary supplemen-
tation with DHA+EPA (70:30 ratio) prevented ventricular remodel-
ing and cardiomyocyte apoptosis in rats with aortic banding, and
increased DHA and EPA and decreased ARA in cardiac phospholipids
[9]. DHA+EPA supplementation also decreased ARA and increased
DHA in cardiolipin (CL) [31], an inner membrane tetra-acyl phospho-
lipid comprised primarily of linoleic acid (18:2n6) that anchors
cytochrome C to themembrane and inhibits apoptosis [21,25]. Dietary
supplementation with DHA+EPA can increase total CL content in
cardiac mitochondria [20,28], and prevent the decline in tetralinoleyl
CL (L4CL), the primary moiety of CL, in hearts subjected to prolonged
aortic constriction [31].
Little is known about the independent effects of DHA and EPA on
cardiacmitochondria. While clinical studies show that the triglyceride
lowering effects of DHA and EPA are equivalent [12], there is evidence
that DHA supplementation is superior to EPA in changing the fatty
acid composition of cardiac phospholipids [30]. DHA is readily
shortened to form EPA, but there is minimal elongation of EPA to
form DHA [22], and appears to not occur in the heart [15]. Thus DHA
supplementation should be more effective at increasing total ω-3
PUFA and decreasing ARA in membrane phospholipids, particularly in
the heart. We hypothesize that dietary supplementation with DHA
causes a greater increase in total ω-3 PUFA and decrease in ω-6 PUFA
in mitochondrial membrane phospholipids than does supplementa-
tion with EPA, and results in a delay in Ca2+-induced MPTP opening,
while EPA does not.
2. Methods
2.1. Experimental design
The animal protocol was conducted according to the Guideline for
the Care and Use of Laboratory Animals (NIH publication 85-23) and
was approved by the University of Maryland School of Medicine
Institutional Animal Care and Use Committee. Investigators were
blinded to treatment when measurements were performed. The
animals were maintained on a reverse 12-h light–dark cycle and all
procedures were performed in the fed state between 3 and 6 h from
the start of the dark phase. Two series of experiments were
performed. In the initial studies (Series 1) male Wistar rats weighing
190–200 g were fed a standard low fat diet (CTRL) or modiﬁed
standard diet containing DHA or EPA at 2.5% of total caloric intake,
which corresponds to a human intake of approximately 5.5 g/day
(calculated assuming an energy intake of 2000 kcal/day and 9 kcal/g
of fat). The rats were maintained on the diet for 8 weeks. Following
dietary treatment, rats were anesthetized with isoﬂurane, blood was
drawn, and the heart was harvested for biochemical analysis and
mitochondrial isolation. Plasma from these animals was analyzed for
free fatty acids and triglyceride levels, and cardiac mitochondria for
respiration, Ca2+ retention capacity, VDAC and cyclophilin D, and
membrane phospholipid composition as described below. Following
completion of Series 1, a second series of animal studies (Series 2)
were performed to assess mitochondrial swelling using a light
scattering assay, and the effects of different respiratory substrates
on Ca2+ retention capacity in mitochondria from control and DHA
supplemented rats. Animals were treated for 10 weeks and were fed
either CTRL or DHA (2.5% of total caloric intake).
2.2. Diets
All diets were custom-manufactured (Research Diets Inc., New
Brunswick, NJ), and had 68% of total energy from carbohydrate (38%
of total energy from cornstarch, 5% from maltodextrin and 25% from
sucrose), 20% protein (casein supplemented with l-cystine) and 12%
energy from fat. In Series 1 the CTRL diet the fat was made up of 35.3%cocoa butter, 39.8% lard, 16.6% soybean oil and 8.3% palm kernel oil
(see Table 1 for fatty acid composition). The DHA diet contained 5.75%
of total energy from algal oil that was comprised of 45.6% DHA by
mass (DHASCO, Martek Inc, Columbia, MD, USA), with the balance
from cocoa butter and soybean oil. The EPA diet had 2.6% of energy
from puriﬁed ﬁsh oil comprised of 95.5% EPA by mass (KD Pharma,
Bexbach, Germany), with the balance from cocoa butter, soybean oil,
safﬂower oil and palm kernel oil. DHA and EPA oils contained ascorbyl
palmitate (250 ppm) and tocopherols (250 ppm) to prevent perox-
idation, which was less than 0.5 meq/kg at the time of manufacture of
the diet. All diets were supplemented with the same amount of
vitamins (Vitamin Mix V10001, 10 g/kg), minerals (Mineral Mix
S10026, 10 g/kg), cellulose (50 g/kg) and choline (2 g/kg). In Series
2, the DHAwas again 2.5% of total energy in the diet, but the diets had
66% of total energy from carbohydrate (54% of total energy from
cornstarch and 12% from maltodextrin), 20% protein (casein supple-
mented with l-cystine) and 14% energy from fat (see Table 1 for fatty
acid composition). In the CTRL diet, the fat was made up of 71.5%
cocoa butter, 17.1% soybean oil, 7.2% palm oil, 2.8% safﬂower oil and
1.4% linseed oil. In the DHA diet, 5.75% of algal oil partially replaced
cocoa butter. Animals were treated for 8 weeks and mitochondria
isolated as in Series 1.2.3. Mitochondrial preparation
Mitochondria were isolated as previously described [24]. LV tissue
(400–500 mg) was minced and homogenized in 1:10 cold modiﬁed
Chappel-Perry buffer (100 mM KCl, 50 mM MOPS, 5 mM MgSO4,
1 mM ATP, 1 mM EGTA, 2 mg/ml BSA), and the homogenates were
centrifuged at 500 ×g. Subsequent centrifugation allowed for separa-
tion and puriﬁcation of the subsarcolemmal mitochondria. The
concentration of mitochondrial protein was measured by the Lowry
method using bovine serum albumin as a standard.
Fig. 1. Serum triglyceride (Left) and free fatty acid concentration (Right). Data are
means of n=6–8/group. *Pb0.05 vs. CTRL.
Table 3
Mitochondrial phospholipid fatty acid composition expressed as molar percent of total
phospholipid fatty acid.
Fatty acid Control DHA EPA
C16:0 12.2±0.8 13.3±0.5 10.8±0.6
C16:1 BQL BQL 4.5±1.8
C18:0 20.0±0.4 18.9±0.5 19.8±0.8
C18:1n9 14.3±0. 8 13.0±1.0 11.8±1.0
C18:1n7 4.5±0.2 3.7±0.2* 4.2±0.2
C18:2n6 22.0±0. 9 23.1±1.0 22.4±0.8
C20:3n6 BQL 1.6±0.2* 1.1±0.2*
C20:4n6 14.6±1.0 5.7±0.2* 9.8±0.8*#
C20:5n3 BQL 4.4±0.3* 6.0±0.2*
C22:6n3 9.1±0.5 14.8±0.6* 8.3±0.2#
Total ω-3 PUFA 9.1±0.5 19.2±0.5* 14.3±0.3*#
Data are expressed as percent of total mitochondrial membrane phospholipid content.
BQL, below the quantiﬁable limit (limit of detection=0.41% of total phospholipid fatty
acids). Data are the mean±SEM. n=7–8/group. *pb0.05 compared to the control
group; #pb0.001 compared to DHA.
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Free fatty acids and triglycerideswere assessed in the plasma using
commercially available kits (Wako, Richmond, VA). Mitochondrial
proteins were separated by electrophoresis in 4–12% NuPage gels,
transferred onto a nitrocellulose membrane, and incubated with
speciﬁc antibodies to cyclophilin D and voltage-dependent anion
channel (VDAC) (1:10,000 and 1:5000, respectively, both from
Mitosciences, Eugene, OR). Fluorescence-conjugated secondary anti-
bodies (IRDye 800, 1:10,000; LI-COR Bioscience) were used for
incubation before the membranes were scanned with Odyssey®
infrared imaging system (LI-COR Bioscience). The digitized image was
analyzed with Odyssey® software.
2.5. Mitochondrial respiration
Mitochondrial oxygen consumption was measured using a Clark-
type oxygen electrode (Qubit Systems, Ontario, Canada). Mitochon-
dria (0.25 mg protein) were suspended in 0.5 ml solution consisting
of 100 mM KCl, 50 mMMOPS, 5 mM KH2PO4 1 mM EGTA, and 0.5 mg
fatty acid-free bovine serum albumin, at pH 7.4 and 37 °C. State 3
(ADP-stimulated) and state 4 (non-phosphorylating) respiration
were measured with glutamate+malate (10 and 5 mM, respective-
ly), pyruvate+malate (10 and 5 mM, respectively) and palmitoyl-
carnitine+malate (40 μM and 5 mM, respectively) to assess
respiration through complex I–IV, while succinate+rotenone
(10 mM and 7.5 μM, respectively) were used to assess respiration
through complex II–IV of the ETC exclusively. State 4 respiration wasFig. 2. Cardiac mitochondrial phospholipid fatty acid composition expressed as percalso measured in the presence of oligomycin to inhibit the
mitochondrial ATP synthase.
2.6. Ca2+ retention capacity
The capacity for mitochondrial to retain Ca2+, an established index
of MPTP opening, was assessed in isolated mitochondrial as
previously described in detail [24]. Brieﬂy, mitochondria (0.5 mg
protein) were suspended in respiration buffer in the absence of
bovine serum albumin and the presence of 5 µM EGTA, 1 mM MgCl2,
10 mM glutamate and 5 mM malate. A 5 mM calcium solution was
continuously infused at a rate of 5 μl/min for 20 min, and free Ca2+
was monitored by use of 0.7 μl Fura-6-F (0.07 mM) at 37 °C using a
ﬂuorescence spectrometer with excitation wavelengths for the free
and calcium-bound forms of 340 and 380 nm, respectively, and
emission wavelength of 550 nm. Opening of the MPTP was deﬁned as
the point where the extramitochondrial [Ca2+] reached twice baseline
values [19].
For Series 2 a high throughput Ca2+ retention assaywas developed
to allow evaluation of the effects of mitochondrial respiratory
substrates on the delay in MPTP induced by DHA supplementation.
The assay wasmodiﬁed from Basso et al. [4], andwas performed using
a 96-well ﬂuorescence plate reader (FLUOstar Optima, BMG Labtech,
Germany). Brieﬂy, 25 µg of mitochondria was resuspended in 200 µl
of the same buffer used above, but with varying substrates; either
glutamate+malate (10 and 5 mM, respectively), pyruvate+malate
(10 and 5 mM, respectively), palmitoylcarnitine+malate (40 μM and
5 mM, respectively) or succinate (10 mM) with rotenone (7.5 μM).entage of total fatty acids. Data are means of n=7–8/group. *Pb0.001 vs. CTRL.
Fig. 3. Cardiac mitochondrial cardiolipin (CL) content for L4CL and L3AA1 (molecular weights of 1448 and 1472, respectively) expressed as percentage of total CL. Data are means of
n=8/group. *Pb0.001 vs. CTRL.
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5N and ﬂuorescence measured at 485 and 538 nm for excitation and
emission wavelengths respectively. Automated additions of 25 nmol
Ca2+/mg mitochondrial protein were performed at regular 7 min
intervals and ﬂuorescence measured every 17 s for 160 min at 37 °C.
2.7. Ca2+-induced swelling
In Series 2 light scattering, an index of Ca2+-induced swelling was
monitored using a 96 well spectrophotometric plate reader (Spec-
traMax, Molecular Devices, USA). Brieﬂy, 25 µg of mitochondria was
resuspended in 200 µl the same buffer as used for the Ca2+ retention
capacity assay. Baseline absorbance at 540 nm was read at 7 s
intervals for 2 min, then either 50 or 100 nmol Ca2+ was rapidly
added to the wells and the absorbance was read for 15 min at 37 °C.Table 4
Mitochondrial respiration.
Control DHA EPA
Glutamate+Malate
State 3 120.2±10.0 115.2±16.2 119.3±13.4
State 4 (− oligomycin) 34.9±2.1 35.3±2.9 32.1±4.8
State 4 (+ oligomycin) 20.4±1.8 17.2±2.0 19.1±3.3
RCR 7.2±1.1 7.0±0. 9 7.0±1.0
P/O 2.57±0.20 2.37±0.18 2.76±0.23
Pyruvate+Malate
State 3 226.6±19.5 240.4±28.7 221.2±31.0
State 4 (− oligomycin) 78.1±4.4 54.0±3.2* 63.5±6.4
State 4 (+ oligomycin) 50.1±4.1 34.8±4.2* 43.3±5.2
RCR 4.5±0.2 7.7±1.0* 5.1±0.3
P/O 2.60±0.17 2.48±0.09 2.44±0.30
Palmityl-carnitine+Malate
State 3 265.2±28.2 265.7±34.4 243.7±28.1
State 4 (− oligomycin) 59.7±4.2 42.6±1.9 59.4±7.0
State 4 (+ Oligomycin) 32.0±3.5 24.9±2.6 29.7±3.8
RCR 8.8±1.0 11.4±1.8 9.5±1.8
P/O 2.46±0.13 2.50±0.12 2.57±0.14
Succinate+Rotenone
State 3 316. 8±31.1 325.2±19.6 307.2±37.1
State 4 (− oligomycin) 105.7±9.7 99.3±7.0 102.1±11.5
State 4 (+ oligomycin) 82.5±9.5 84.7±10.1 80.3±11.7
RCR 4.1±0.4 4.1±0.4 4.1±0.5
P/O 1.57±0.09 1.48±0.06 1.48±0.08
Data are themean±SEM. n=7 or 8/group. All Rates are expressed in ng atoms Omg−1
min−1. *pb0.05 compared to the control group. The RCR, deﬁned as the ratio of State 3
to State 4 respiration rate, was calculated from the State 4 rate with oligomycin. The
P/O ratio was calculated from measurements made without oligomycin.2.8. Membrane lipid composition
Cardiac phospholipid fatty acid composition was assessed in a
subset of animals from Series 1 (n=7–9/group) on isolated cardiac
mitochondria homogenates by gas chromatography with a ﬂame
ionization detector according to a modiﬁcation of the transesteriﬁca-
tion method as previously described [24]. CL composition was
assessed on isolated cardiac mitochondria by electrospray ionization
mass spectrometry using 1,1′,2,2′-tetramyristoyl CL as an internal
standard as previously described (n=9/group) [24,31,32].Fig. 4. Effect of diet on the Ca2+ retention capacity. Upper panel: The fraction of
preparations with the MPTP open plotted as a function of the cumulative amount of Ca2+
added to the cuvette containing isolatedmitochondria. Lower panel:MeanCa2+ infused to
initiate MPTP opening. Data are means of n=8–9/group.
Table 6
Western blot results for VDAC1, VDAC2 and cyclophilin D in isolated mitochondria as
assessed by densitometry. There were no differences among groups.
CTRL DHA EPA
VDAC 1 1.00±0.13 1.03±0.22 0.87±0.16
VDAC 2 1.00±0.15 1.02±0.20 0.94±0.17
Cyclophilin D 1.00±0.08 1.01±0.10 1.00±0.08
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Mean values are presented±SEM, and the level of signiﬁcancewas
set at pb0.05. Comparisons between groups were made with a one-
way analysis of variance (ANOVA) and the Bonferroni post hoc test.
Analysis of non-normal data sets was done with Kruskal–Wallis
ANOVA on ranks and post hoc comparisons were made using Dunn's
method. A two-way repeated measure ANOVA with a Holm-Sidak
post hoc test was performed when appropriate.3. Results
Body and cardiac masses were unaffected by diet (Table 2) and
mitochondrial yield not was different among groups. EPA and DHA
lowered plasma free fatty acid and triglyceride concentrations to a
similar extent compared to CTRL (Fig. 1), as previously shown in
humans [12].3.1. Mitochondrial phospholipid composition
EPAwas not detected in the CTRL group. The DHA diet signiﬁcantly
increased DHA and EPA, and decreased ARA in mitochondrial
phospholipids. On the other hand, the EPA diet did not affect DHA
levels, and onlymodestly decreased ARA levels, and increased EPA in a
manner similar to treatment with DHA (Fig. 2). Dihomogammalino-
lenic acid (20:3n6), an intermediate in the synthesis of ARA from
linoleic acid, was not detected in the CTRL group, but was increased to
a similar extent by supplementation with either DHA or EPA (pb0.05)
(Table 3). The composition of CL was altered by DHA, showing an
increase in L4CL (Fig. 3), the major and most critical species of CL [33].
In addition, there was a trend to increase total CL content in the DHA
group compared to CTRL (pb0.08), with no effect in the EPA treated
animals (Table 5). There was a decrease in CL species containing one
ARA and three linoleic acid moieties (ARA1L3CL) in both DHA and EPA
groups compared to CTRL (Fig. 3).3.2. Mitochondrial respiration
State 3 respiration with glutamate+malate, pyruvate+malate,
palmitoylcarnitine+malate, or succinate+rotenone as substrates was
unaffected by dietary treatment. DHA treatment decreased state 4
respirationby 30% and the increasedRCRby70%withpyruvate+malate
as the substrate in both the absence and presence of oligomycin to
eliminate anyATP turnover (pb0.05) (Table 4); treatmentwith EPA had
no effect. Neither state 4 respiration or the respiratory control ratio
(RCR) with glutamate+malate, palmitoylcarnitine+malate, or succi-
nate+rotenone as substrates were affected by treatment (Table 4). The
P/O ratio (ADP added/Oxygen consumed) was not different among
groups with any of the substrates (Table 4), indicating no change in
respiratory coupling.Table 5
Mitochondrial cardiolipin (CL) composition.
CTRL DHA EPA
CL species (in mol% of total)
1422 6.78±0.38 6.24±0.37 6.65±0.37
1450 2.61±1.13 0.44±0.38 2.09±1.20
1474 3.61±0.24 2.98±0.31 2.51±0.27
1496 6.46±1.01 5.24±0.60 5.08±0.61
1498 1.11±0.54 0.67±0.28 1.70±0.68
1520 0.89±0.13 0.76±0.07 1.00±0.11
1522 0.73±0.11 0.91±0.13 0.64±0.11
1546 2.14±0.41 1.73±0.35 1.74±0.29
Total CL (in nmol/mg mito protein) 10.72±0.82 13.19±0.85 11.10±0.763.3. Ca2+ retention capacity
Compared to the CTRL and EPA treated groups, DHA signiﬁcantly
increased theCa2+ retention capacity, an index ofMPTP opening (Fig. 4).
As expected, additionof 100 nMCsA lead to a signiﬁcant increase inCa2+
required to elicit MPTP in the CTRL group (83.0±8.7 nmol Ca2+/mg
mito prot vs. 144.8±20.0, pb0.05) and a similar effect in the EPA group
(80.8±4.9 vs. 130.6±12.8,pb0.05). Therewasnodifference in theDHA
group with the addition of CsA (134.9±11.4 vs. 147.0±17.3, NS).
Cyclophilin-D is a key regulatory component of the MPTP [3], however
Westernblot analysis foundnoeffectof anydiet on cyclophilin-Dprotein
expression (Table 5). The voltage-dependent anion channel (VDAC) has
been proposed to play a role in regulation of theMPTP, however protein
expression of VDAC1 and VDAC2 was similar among groups (Table 6).
In Series 2, we used a high throughput assay to compare Ca2+
retention capacity of mitochondria from DHA supplemented hearts to
CTRL, in the presence of different respiratory substrates. First, in the
control diet, there was a decreased Ca2+ retention capacity with
palmitoylcarnitine+malate when compared to glutamate+malate
or succinate+rotenone (pb0.007; Fig. 5), and a strong trend when
compared to pyruvate+malate (p=0.057). Mitochondria from rats
supplemented with DHA had signiﬁcantly enhanced Ca2+ retention
capacity compared to CTRL animals, as reﬂected in lower extra-
mitochondrial Ca2+ for a given cumulative Ca2+ load with all
substrates except palmitoylcarnitine+malate (Fig. 6).
3.4. Mitochondrial swelling
In the mitochondria from CTRL rats there was a dose-dependent
decrease in absorbance at 540 nmwith the addition of Ca2+, whichwas
signiﬁcantly attenuated with DHA supplementation (Figs. 7 and 8).Fig. 5. Effect of different respiratory substrates on the Ca+ retention capacity of CTRL
mitochondria. Data are means of n=10–11/group. *pb0.05, palmitoylcarnitine+malate
vs. glutamate+malate. $pb0.05, palmitoylcarnitine+malate vs. succinate+rotenone.
#pb0.05, palmitoylcarnitine+malate vs. pyruvate+malate.
Fig. 7. Effect of DHA onmitochondrial Ca2+ induced swelling. Ca2+was added at time 0.
Vehicle treated wells had stable absorbance over the 15 min of observation (data not
shown). Data are means of n=9/group.
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The novel ﬁndings of this study are 1) DHA supplementation
delayedMPTPopening in response to Ca2+ compared to animals fed the
standard diet or supplementedwith EPA, and 2) this effect is associated
with a greater increase in total ω-3 PUFA in cardiac mitochondrial
phospholipids with DHA supplementation compared to EPA, which
corresponds with a greater reduction in the amount of ARA and an
increase in L4CL. These differences between DHA and EPA occurred
despite equivalent triglyceride lowering effects in the present investi-
gation and in clinical studies [12,22], suggesting that the lipid lowering
effects of DHA and EPA are independent of phospholipid remodeling, as
previously proposed [16]. Thus the results of the present study show a
novel and potentially important difference between DHA and EPA
supplementation: DHA causes more extensive alterations in mitochon-
drial phospholipid fatty acid composition and delays Ca2+-induced
MPTP opening, despite lipid lowering effects that are similar to EPA.
Opening of the MPTP contributes to cardiac pathology with acute
stress associatedwith ischemia/reperfusion orwith the chronic stress of
heart failure, thus interventions that prevent MPTP opening may have
profound clinical importance [17]. Long term treatment with pharma-
cological doses ofDHAmaypreventMPTP and cardiomyocyte apoptosis,
and improve clinical outcome in ischemicheart disease andheart failure.
We previously showed that dietary supplementationwith amixture of
DHA+EPA(70:30) prevented left ventricular dysfunction and lowered
cardiomyocyte apoptosis in rats subjected to chronic arterial pressure
overload, suggesting that MPTP opening was prevented [9]. Additional
studies are needed to assess the effect of treatmentwith DHAonMPTP,
apoptosis andmyocardial dysfunction and injury in hearts subjected to
ischemia/reperfusion, and in models of heart failure.Fig. 6. Effect of DHA on mitochondrial Ca2+ retention capacity in the presence of differenThe molecular mechanisms by which DHA supplementation delays
Ca2+-inducedMPTP opening are not clear. The structure of theMPTP and
its interaction with the membrane phospholipid environment ist respiratory substrates. Data are means of n=9–11/group. *pb0.05, CTRL vs. DHA.
Fig. 8. Effects of DHA on Ca2+-induced mitochondrial swelling as assessed from the
relative change in absorbance from 0 to 15 min. Data are means of n=9/group. *pb0.05,
CTRL vs. DHA within same Ca2+ dose. #pb0.05, no Ca2+ vs. 2 µmol Ca2+/mg
mitochondrial protein. $pb0.05, 2 µmol Ca2+/mg mitochondrial protein vs. 4 µmol
Ca2+/mg mitochondrial protein.
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previously been implicated in MPTP opening [26,29], suggesting the
association between the decline in ARA in mitochondrial phospholipids
and delay in Ca2+-inducedMPTP observed in the present investigation is
causal. Inhibition of ARA release from membranes reduced myocardial
infarct size following I/R, and this effect was lost by concurrent perfusion
with free ARA [35]. Similarly, inhibition of ARA release in isolated renal
mitochondria preventedMPTPopening andadditionof freeARA restored
MPTP [18]. Similar results are observed in liver mitochondria and
cultured cells [26,29]. Clearly additional studies are needed to fully assess
the role of depletion of ARA in possibly mediating the effects of DHA on
MPTP opening in cardiac mitochondria. It is important to note that
although EPA signiﬁcantly decreased membrane ARA, it did not affect
measures of Ca2+-induced MPTP opening. It is possible that a threshold
content of ARA is necessary to elicit the differences observed with DHA
feeding. Alternatively, the delay in calcium-induced MPTP might not be
due toadecrease inmembraneARA, but rather attributable toan increase
in membrane DHA, which is completely unaffected by EPA feeding.
Previous studies show that MPTP opening is delayed in cardiac
mitochondria by the addition of CsA [13]. In the present investigation
we observed that CsA delayed Ca2+-induced MPTP opening in rats
fed either the standard diet or EPA, but not with DHA supplemen-
tation. This ﬁnding is in contrast to our recent observation that
supplementation with DHA+EPA (70:30) delayed MPTP opening
compared to a standard diet, with a further delay in pore opening in
both groups with the addition of CsA. CsA inhibits MPTP by binding
to cyclophilin-D [6,14], however in the present study we found no
effect of DHA supplementation on mitochondrial cyclophilin-D
content, suggesting the loss of the CsA effect on MPTP was not due
to changes in cyclophilin-D. Furthermore, DHA supplementation had
no effect on the Ca2+ retention capacity of mitochondria in the
presence of palmitoylcarnitine+malate as respiratory substrates.
However, this substrate also decreased the capacity of mitochondria
to retain Ca2+ when compared to other substrates in animals fed the
CTRL diet. Previous studies suggest that lipid mediators can induce
pathological processes in mitochondria [7,10], and a high concen-
tration of either palmitic or arachidonic acid can induce MPTP in
isolated mitochondria [29]. It is possible that MPTP is sensitized and
Ca2+ retention capacity is decreased by the relatively high
concentration of palmitoylcarnititne (40 μM) required to support
respiration in our preparation.
In summary, dietary supplementation with DHA but not EPA
profoundly altered mitochondrial phospholipid fatty acid composi-tion by increasing DHA and depleting ARA, and delaying Ca2+-
induced MPTP opening. This suggest novel and potentially important
differences between DHA and EPA supplementation: DHA causes
more extensive alterations in mitochondrial phospholipid fatty acid
composition and delays Ca2+-induced MPTP opening, despite lipid
lowering effects that are similar to EPA. These results suggest a novel
pharmacological effect of DHA, and suggest that clinical treatment
with DHA may exert greater cardioprotective beneﬁt than treatment
with standard ﬁsh oil formulations that are high in EPA.
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